Matthew R. Smith

Supplementary Figure 1. Nonclinical Mechanisms of Potential Ineffective Dual AR/GR Inhibition

Supplementary Table 2.ctDNA Data for 29 and cfRNA Data for 26 Patients in Dose

Supplementary Table 1. Representativeness of Study Participants

Supplementary Table 1. Representativeness of Study Participants

Supplementary Table 3. Key Tumor Characteristics (AR Resistance Variants, AVPC Molecular Features, and GR Status) of Patients in Dose Expansion

Supplementary Table 3. Key Tumor Characteristics (AR Resistance Variants, AVPC Molecular Features, and GR Status) of Patients in Dose Expansion

Supplementary Table 2.ctDNA Data for 29 and cfRNA Data for 26 Patients in Dose

Supplementary Figure 1. Nonclinical Mechanisms of Potential Ineffective Dual AR/GR Inhibition

Purpose: Increased glucocorticoid receptor (GR) signaling is a proposed compensatory mechanism of resistance to androgen receptor (AR) inhibition in metastatic castration-resistant prostate cancer (mCRPC). ORIC-101 is a potent and selective orally-bioavailable GR antagonist. Patients and Methods: Safety, pharmacokinetic/pharmacodynamic, and antitumor activity of ORIC-101 in combination with enzalutamide were studied in patients with mCRPC progressing on enzalutamide. ORIC-101 doses ranging from 80 to 240 mg once daily were tested in combination with enzalutamide 160 mg once daily. Pharmacokinetics/pharmacodynamics was assessed after a single dose and at steady state. Disease control rate (DCR) at 12 weeks was evaluated at the recommended phase 2 dose (RP2D). Results: A total of 41 patients were enrolled. There were no dose-limiting toxicities and the RP2D was selected as 240 mg of ORIC-101 and 160 mg of enzalutamide daily. At the RP2D, the most common treatment-related adverse events were fatigue (38.7%), nausea (29.0%), decreased appetite (19.4%), and constipation (12.9%). Pharmacokinetic/pharmacodynamic data confirmed ORIC-101 achieved exposures necessary for GR target engagement. Overall, for 31 patients treated at the RP2D, there was insufficient clinical benefit based on DCR (25.8%; 80% confidence interval: 15.65–38.52) which did not meet the prespecified target rate, leading to termination of the study. Exploratory subgroup analyses based on baseline GR expression, presence of AR resistance variants, and molecular features of aggressive variant prostate cancer suggested possible benefit in patients with high GR expression and no other resistance markers, although this would require confirmation. Conclusions: Although the combination of ORIC-101 and enzalutamide demonstrated an acceptable tolerability profile, GR target inhibition with ORIC-101 did not produce clinical benefit in men with metastatic prostate cancer resistant to enzalutamide.